ArticleTherapeutic advances in medical oncology2025
Clinical outcomes and prognostic factors of stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival and patterns of recurrence in patients with nasopharyngeal carcinoma from a non-endemic region-A German multicenter analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for metastatic nasopharyngeal carcinoma (mNPC) remains poor, and effective treatment options are still limited. Objectives: This study aims to evaluate the efficacy of stereotactic body radiation therapy (SBRT) and identify prognostic factors in patients with mNPC. Design: A retrospective study. Methods: From August 2019 to November 2023, this retrospective study included 62 mNPC patients with 84 metastatic lesions treated with SBRT. The primary endpoint was progression-free survival (PFS). PFS1, PFS2, and overall survival (OS) were also assessed, and related prognostic factors were analyzed. Results: The median follow-up time from the diagnosis of metastasis was 44 months (range from 12 to 85 months). Combining SBRT with systemic therapy resulted in favorable survival outcomes, with 3-year PFS, PFS1, PFS2, OS, and local control rates of 35.5%, 35.7%, 56.1%, 87.2%, and 86.5%, respectively. The combination of SBRT with first-line systemic therapy, disease control before SBRT, oligometastatic disease, and SBRT to all metastatic lesions exhibited superior PFS, PFS1, and PFS2. Multivariable analysis indicated that the line of SBRT treatment was a predictor of PFS1 and PFS2, and SBRT to all metastatic lesions was a predictor of all PFSs. Conclusion: SBRT is an effective and safe local treatment for mNPC patients. Early intervention with SBRT during first-line therapy and SBRT to all metastatic sites for oligometastatic disease may help improve disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.